Skip to main content
IL DONG PHARMACEUTICAL CO., LTD. logo

IL DONG PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 249420 ISIN · KR7249420001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-07-30 Earnings Release
Country KR South Korea
Listing KO 249420

About IL DONG PHARMACEUTICAL CO., LTD.

https://mobile.ildong.com/eng/main/main…

IL DONG PHARMACEUTICAL CO., LTD. is a pharmaceutical company engaged in the research, development, manufacturing, and commercialization of a broad range of healthcare products. The company's portfolio encompasses ethical drugs, over-the-counter (OTC) medications, active pharmaceutical ingredients (APIs), and health functional foods. Key therapeutic areas of focus include metabolic disorders, gastrointestinal diseases, degenerative diseases, oncology, and cardiovascular conditions. Its robust research and development pipeline features promising drug candidates such as an oral GLP-1 receptor agonist for diabetes and obesity, a P-CAB class treatment for peptic ulcers, and a first-in-class CXCR7 agonist for fibrotic diseases. Utilizing its GMP-certified facilities, the company also offers contract manufacturing (CMO) services, with specialized capabilities in antibiotics and oncology drugs, while actively pursuing global expansion through strategic partnerships and licensing.

Recent filings

Filing Released Lang Actions
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Ildong Pharmaceutical for the second quarter of 2025. It provides key financial highlights such as revenue, operating profit, and net income, explicitly stating these are provisional figures (잠정치) subject to change. This fits the definition of an Earnings Release (ER) as it is an initial announcement of periodical financial results. Q2 2025
2025-07-30 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (잠정실적) for Ildong Pharmaceutical, detailing quarterly financial performance (revenue, operating profit, net income) for Q2 2025. It provides key financial highlights and is explicitly labeled as a preliminary disclosure (잠정치) subject to audit. This fits the definition of an Earnings Release (ER) as it provides the initial announcement of periodic financial results. Q2 2025
2025-07-30 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory disclosure from Ildong Pharmaceutical regarding the acquisition of shares in another company (Ildong Bioscience). It details the transaction amount, purpose, board approval, and financial status of the target company. This type of corporate action, involving the acquisition of equity in another entity, is classified as M&A activity (TAR) within the provided filing categories.
2025-07-30 Korean
결산실적공시예고(안내공시)
Report Publication Announcement Classification · 100% confidence The document is a short announcement (579 characters) from Ildong Pharmaceutical notifying the public of the upcoming date for their financial results disclosure (2025-07-30). It explicitly states that the actual financial data will be published on that future date. Following the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, making it a Report Publication Announcement (RPA).
2025-07-28 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by a specific entity (DB Ildong Best No. 3) in a listed company (Ildong Pharmaceutical). This type of disclosure is a mandatory regulatory requirement for significant shareholders to report their holdings and changes therein to the Financial Supervisory Service (FSS) and the Korea Exchange (KRX). It falls under the 'Major Shareholding Notification' category.
2025-07-22 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. This type of filing is required under the Capital Markets Act when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). It details the identity of the holder, the number of shares held, and the purpose of the holding (in this case, simple investment). This corresponds to the 'Major Shareholding Notification' category.
2025-07-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.